GALECTIN THERAPEUTICS INC 10-Q

Item 5. Other Information Not Applicable Item 6. Exhibits Exhibit Number Description of Document Note Reference 31.1* Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 31.2* Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 32.1** Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2** Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS* XBRL Instance Document the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document 101.SCH* XBRL Taxonomy Extension Schema Document 101.CAL* XBRL Taxonomy Calculation Linkbase Document 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* XBRL Taxonomy Label Linkbase Document 101.PRE* XBRL Taxonomy Presentation Linkbase Document 104* Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101) * Filed herewith. ** Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. 25 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 9, 2020. GALECTIN THERAPEUTICS INC. By: /s/ Joel Lewis Name: Joel Lewis Title: Chief Executive Officer and President (principal executive officer) By: /s/ Jack W. Callicutt Name: Jack W. Callicutt Title: Chief Financial Officer (principal financial and accounting officer) 26